Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...

Dear C.D.: It seems to me that we humans have a protective mechanism that lets us forget just how sick we were when we had ...

Three Motley Fool contributors think they've found no-brainer healthcare stocks to buy in May. Here's why they picked Eli ...

Sometimes, it makes sense to skip insurance and instead take advantage of a health savings account or flexible savings ...

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

NEW YORK (AP) — More U.S. children have died this flu season than at any time since the swine flu pandemic 15 years ago, according to a federal report released Friday. The 216 pediatric deaths ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...

Tim Friede has been bitten by snakes hundreds of times — often on purpose. Now scientists are studying his blood in hopes of ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.